Sentences with phrase «professor of cancer therapy»

Óscar Fernandez - Capetillo, professor of cancer therapy at Karolinska Institutet since 2015 and a SciLifeLab faculty member, has been awarded the Erik K Fernström prize for his pioneering research on how DNA damage can lead to cancer and ageing.

Not exact matches

Publishing a commentary about Bitcoin by an institutional economics professor is as responsible as letting a village witch doctor give lectures on the merits of proton radiation therapy to treat cancer («The Bitcoin myth,» March 3).

Synthetic marijuana was first developed in the South Carolina lab of a Clemson University professor as part of research into therapies for osteoporosis, liver disease and some kinds of cancer.

«Despite new therapies, it's virtually inevitable that a patient with multiple myeloma will experience relapse of the disease at some point,» said senior author Catriona Jamieson, MD, PhD, professor of medicine, Koman Family Presidential Endowed Chair in Cancer Research and chief of the Division of Regenerative Medicine at UC San Diego School of Medicine.

«These new drugs are opening the door for more avenues of targeted therapy for the future,» says American Cancer Society president Ralph Vance, a professor of medicine at the University of Mississippi School of Medicine.

The findings — published today in Nature — provide significant insights into cell types fated to relapse and can help accelerate the quest for new, upfront therapies, says Dr. Dick, a Senior Scientist at Princess Margaret Cancer Centre, University Health Network, and Professor in the Department of Molecular Genetics, University of Toronto.

«This study forms the basis for future research in patients with breast cancer and offers hope for targeted therapy for patients with aggressive triple - negative inflammatory breast cancer,» said lead researcher Mateusz Opyrchal, M.D., Ph.D., Assistant Professor of Oncology at RPCI.

«The study results are extremely suggestive that changes in diet might impact both how an individual responds to primary therapy and their chances of lethal disease spreading later in life,» said the study's senior author, Gregory J. Hannon, PhD, professor of Cancer Molecular Biology and director, Cancer Research UK Cambridge Institute, University of Cambridge in England.

Professor Ali Tavassoli, who led the study with colleague Dr. Ishna Mistry, explains: «In an effort to better understand the role of HIF - 1 in cancer, and to demonstrate the potential for inhibiting this protein in cancer therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF - 1 inhibiting molecule when placed in a hypoxic environment.

«A significant number of advanced prostate cancer patients treated with a chemical castration therapy called androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic, castration - resistant prostate cancer,» said Ronald DePinho, M.D., professor of Cancer Bicancer patients treated with a chemical castration therapy called androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic, castration - resistant prostate cancer,» said Ronald DePinho, M.D., professor of Cancer Bicancer,» said Ronald DePinho, M.D., professor of Cancer BiCancer Biology.

«It was kind of fun being at a medical school and known as the weird guy who worked with dogs,» says Modiano, who is now a professor of comparative oncology at the University of Minnesota College of Veterinary Medicine and the Masonic Cancer Center, where his research focuses on immunology, cancer cell biology, cancer genetics, and applications of gene thCancer Center, where his research focuses on immunology, cancer cell biology, cancer genetics, and applications of gene thcancer cell biology, cancer genetics, and applications of gene thcancer genetics, and applications of gene therapy.

«This is a step forward in understanding pancreatic cancer's resistance to standard therapies,» said principal investigator Gregory Beatty, MD, PhD, an assistant professor of Hematology / Oncology at Penn and a member of Penn's Abramson Cancer Ccancer's resistance to standard therapies,» said principal investigator Gregory Beatty, MD, PhD, an assistant professor of Hematology / Oncology at Penn and a member of Penn's Abramson Cancer CCancer Center.

«This study opens the door for combination therapy with BRAF inhibitors and autophagy inhibitors, which haven't been explored deeply as a therapeutic option for patients whose tumors are resistant,» said Ravi K. Amaravadi, MD, assistant professor of Medicine in the division of Hematology / Oncology at the Perelman School of Medicine and co-leader of the Cancer Therapeutics Program at Penn Medicine's Abramson Cancer Center.

«One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum - resistant patients with recurrent or persistent disease,» said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston.

«Breast cancer stem cells pose a serious problem for therapy,» says lead study investigator Gregg Semenza, M.D., Ph.D., the C. Michael Armstrong Professor of Medicine, director of the Vascular Biology Program at the Johns Hopkins Institute for Cell Engineering and a member of the Johns Hopkins Kimmel Cancer Ccancer stem cells pose a serious problem for therapy,» says lead study investigator Gregg Semenza, M.D., Ph.D., the C. Michael Armstrong Professor of Medicine, director of the Vascular Biology Program at the Johns Hopkins Institute for Cell Engineering and a member of the Johns Hopkins Kimmel Cancer CCancer Center.

Presenting these results at the 3rd ESTRO Forum in Barcelona, Spain, today (Monday) Professor James Morris, from the Department of Radiation Oncology, Vancouver Cancer Centre, British Columbia Cancer Agency (BCCA), Vancouver, Canada, will say that the ASCENDE - RT1 trial is the first and only existing trial comparing low - dose - rate prostate brachytherapy (LDR - PB) for the curative treatment of prostate cancer with any other method of radiation therapy delCancer Centre, British Columbia Cancer Agency (BCCA), Vancouver, Canada, will say that the ASCENDE - RT1 trial is the first and only existing trial comparing low - dose - rate prostate brachytherapy (LDR - PB) for the curative treatment of prostate cancer with any other method of radiation therapy delCancer Agency (BCCA), Vancouver, Canada, will say that the ASCENDE - RT1 trial is the first and only existing trial comparing low - dose - rate prostate brachytherapy (LDR - PB) for the curative treatment of prostate cancer with any other method of radiation therapy delcancer with any other method of radiation therapy delivery.

«Oncologists here at Moores Cancer Center at UC San Diego Health and elsewhere can often personalize cancer therapy based on an individual patient's unique cancer mutations,» said senior author Trey Ideker, PhD, professor of genetics at UC San Diego School of MedCancer Center at UC San Diego Health and elsewhere can often personalize cancer therapy based on an individual patient's unique cancer mutations,» said senior author Trey Ideker, PhD, professor of genetics at UC San Diego School of Medcancer therapy based on an individual patient's unique cancer mutations,» said senior author Trey Ideker, PhD, professor of genetics at UC San Diego School of Medcancer mutations,» said senior author Trey Ideker, PhD, professor of genetics at UC San Diego School of Medicine.

Ben Stanger, MD, PhD, a professor in the division of Gastroenterology, and first author Ravi Maddipati, MD, an instructor in the division of Gastroenterology, say that these results may prove useful in designing better targeted therapies to stop tumor progression and provide an improved non-invasive method for detecting early disease states in this highly lethal cancer.

Led by Joke Bradt, PhD, associate professor in Drexel University's College of Nursing and Health Professions, a team looked into studies that examined the impact of music therapy (a personalized music experience offered by trained music therapists) and music medicine (listening to pre-recorded music provided by a doctor or nurse) on psychological and physical outcomes in people with cancer.

«Identifying targets essential to cell survival in tumor suppressor genes has long been an investigational goal with the aim of offering cancer - specific vulnerabilities for targeted therapy,» said Ronald DePinho, M.D., professor of Cancer Biology, MD Anderson president, and senior author for the Nature cancer - specific vulnerabilities for targeted therapy,» said Ronald DePinho, M.D., professor of Cancer Biology, MD Anderson president, and senior author for the Nature Cancer Biology, MD Anderson president, and senior author for the Nature paper.

«By helping us understand that lower levels of RNF125 confer resistance to BRAF inhibitors, we have a new strategy to stratify patients for currently approved therapy versus participation for human clinical trials to investigate whether targeting JAK1 will be more effective in patients whose tumors exhibit reduced RNF125,» said Keith T. Flaherty, M.D., associate professor, Harvard Medical School, and director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital, and co-author of the study.

«The good news is that this finding predicts that patients missing either gene should be sensitive to new therapies targeting focal adhesion enzymes, which are currently being tested in early - stage clinical trials,» says Shaw, who is also a member of the Moores Cancer Center and an adjunct professor at the University of California, San Diego.

«Patients with non-small cell lung cancer (NSCLC) should receive front line therapy with the anaplastic lymphoma kinase (ALK) inhibitor crizotinib,» said lead author Professor Giorgio Scagliotti, head of the Department of Oncology, University of Turin, Italy.

Dr. Jones obtained his Ph.D. in 2003 from the University of Birmingham Institute of Cancer and Genomic Sciences (United Kingdom) under Professor Lawrence Young, studying the use of gene therapy for targeting Epstein - Barr Virus (EBV) proteins with replication - competent adenoviruses to treat EBV - driven malignancies.

«We still have a long way to go and many challenges to overcome before we will have therapies that are ready for clinical use, but this is a significant first step in the process,» says Emdad, member of the Cancer Molecular Genetics research program at Massey, assistant professor in the VCU Department of Human and Molecular Genetics and member of the VIMM.

«Even when the genes driving cancer are known, clinicians don't have an efficient way to choose among the hundreds of possible drug therapies,» said study leader Kai Wang, PhD, associate professor of biomedical informatics and director of clinical informatics at the Institute for Genomic Medicine at CUMC.

«The link between metabolism and cancer has been proposed or inferred to exist for a long time, but what is more scarce is evidence for a direct connection — genetic mutations in metabolic enzymes,» said senior author Ricardo C.T. Aguiar, M.D., Ph.D., associate professor of hematology - oncology in the School of Medicine and a faculty scientist with the Cancer Therapy & Research Center (CTRC) at the UT Health Science Center and the South Texas Veterans Health Care System, Audie L. Murphy Divcancer has been proposed or inferred to exist for a long time, but what is more scarce is evidence for a direct connection — genetic mutations in metabolic enzymes,» said senior author Ricardo C.T. Aguiar, M.D., Ph.D., associate professor of hematology - oncology in the School of Medicine and a faculty scientist with the Cancer Therapy & Research Center (CTRC) at the UT Health Science Center and the South Texas Veterans Health Care System, Audie L. Murphy DivCancer Therapy & Research Center (CTRC) at the UT Health Science Center and the South Texas Veterans Health Care System, Audie L. Murphy Division.

Nevertheless, trying to develop new therapies based on what treatments will look like in the coming decade is a nearly impossible task, points out Michael Stratton, joint head of the Cancer Genome Project and professor of cancer genetics at the University of London's Institute of Cancer Research, who has been working on developing finely targeted cancer treatments since identifying the BRAF oncogene inCancer Genome Project and professor of cancer genetics at the University of London's Institute of Cancer Research, who has been working on developing finely targeted cancer treatments since identifying the BRAF oncogene incancer genetics at the University of London's Institute of Cancer Research, who has been working on developing finely targeted cancer treatments since identifying the BRAF oncogene inCancer Research, who has been working on developing finely targeted cancer treatments since identifying the BRAF oncogene incancer treatments since identifying the BRAF oncogene in 2002.

«Because of relatively low survival rates and their advancing age, these patients tend to be poor candidates for aggressive therapies, like a bone marrow transplant,» said senior author Catriona Jamieson, MD, PhD, professor of medicine, chief of the Division of Regenerative Medicine at UC San Diego School of Medicine and director of the Stem Cell Research Program at Moores Cancer Center.

The technology to grow NK cells from umbilical cord blood was developed by Nina Shah, M.D., assistant professor and Elizabeth J. Shpall, M.D., professor in the department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center.

«This groundbreaking study sets the stage for more exacting research, using the latest genomic technologies and aimed at developing new therapies that could help the tens of thousand of patients who urgently need our help,» said Dr. Nhan Tran, an Associate Professor of TGen's Cancer and Cell Biology Division and the study's other co-senior author.

In a letter published in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapy.

«We thought that patients who have CFS breaks might be more sensitive to radiation therapy - induced DNA damage,» said the lead author of the study, Robert G. Bristow, MD, PhD, a Professor within the radiation oncology and medical biophysics departments at the University of Toronto; and a Clinician - Scientist at the Princess Margaret Cancer Centre in Toronto.

«It takes a long time to develop new genetic therapies, and it's a huge investment,» says Orkin, who is also chairman of pediatric oncology at Dana - Farber Cancer Institute, associate chief of hematology - oncology at Boston Children's Hospital and professor of pediatrics at Harvard Medical School.

«Our case studies showed similar survival with the use of stereotactic radiation therapy compared with surgery,» said lead author Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and co-leader of the Kidney Cancer Program at the Harold C. Simmons Comprehensive Cancer Center.

Professor Jean - Charles Soria, Chairman of the Drug Development Department at Gustave Roussy Cancer campus, France, will tell the Symposium: «Currently, there are no approved targeted therapies for mutant EGFR lung cancer patients who develop the T790M mutation, which means their disease inevitably will get Cancer campus, France, will tell the Symposium: «Currently, there are no approved targeted therapies for mutant EGFR lung cancer patients who develop the T790M mutation, which means their disease inevitably will get cancer patients who develop the T790M mutation, which means their disease inevitably will get worse.

«There was some skepticism about whether a CD19 - directed therapy would work in this disease, since nearly all of these patients» cancerous plasma cells do not express CD19,» said the study's senior author, Edward Stadtmauer, MD, chief of Hematologic Malignancies and a professor of Hematology / Oncology in Penn's Abramson Cancer Center and Perelman School of Medicine.

«Most renal cell carcinomas learn to escape therapy after a couple of years,» said Robert Weiss, professor of medicine at UC Davis, chief of nephrology at Sacramento VA Medical Center, and head of the kidney cancer working group at the UC Davis Comprehensive Cancer Ccancer working group at the UC Davis Comprehensive Cancer CCancer Center.

«Until now, physicians have taken a «wait and see» approach to antiviral therapies following transplantation,» says Toor, a hematologist - oncologist in the Bone Marrow Transplant Program and member of the Developmental Therapeutics research program at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine.

«Checkpoint inhibitors are one of the most exciting recent advances for cancers, but the mechanism by which most patients become resistant to these therapies has been a mystery,» says Victor E. Velculescu, M.D., Ph.D., program leader in the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and professor of oncology.

Last week, Lin Zhang, MD, an associate professor of Obstetrics and Gynecology, described in Science Translational Medicine, how his team treated therapy resistant cancer cells to renew their sensitivity to PARP inhibitors, a class of drugs that, when effective, prevent cancer cells from keeping up with DNA repair, causing them to eventually die.

The more it's expressed only on cancer cells, the more targeted the therapy becomes,» says Colin Weekes, MD, PhD, CU Cancer Center investigator and assistant professor in the Division of Oncology at the CU School of Medcancer cells, the more targeted the therapy becomes,» says Colin Weekes, MD, PhD, CU Cancer Center investigator and assistant professor in the Division of Oncology at the CU School of MedCancer Center investigator and assistant professor in the Division of Oncology at the CU School of Medicine.

Coupled with a review of these results by experts on a molecular tumor board, the opportunity exists to identify novel therapies that would target specific abnormalities,» notes senior author of the work, Shridar Ganesan, MD, PhD, associate director for translational science at Rutgers Cancer Institute and associate professor of medicine and pharmacology at Rutgers Robert Wood Johnson Medical School.

«This study, one of only a few large studies to have follow - up beyond five years, demonstrates that patients who have head and neck cancers and who are being treated with radiation therapy alone have improved local - regional control and no increase in late toxicity when radiation therapy is delivered twice a day in two smaller doses which we call hyperfractionation,» said Jonathan J. Beitler, MD, MBA, FASTRO, lead author of the study and professor of radiation oncology, otolaryngology and hematology / medical oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta.

«Everybody out there working in the cancer space is trying to figure out ways to enhance checkpoint blockade immunotherapy,» said Wenbin Lin, James Franck Professor in Chemistry at UChicago and one of the scientists who conceived the new therapy.

Reporting in the Journal of Clinical Investigation Insights, a team led by senior author Andrea Facciabene, PhD, a research assistant professor of Radiation Oncology and Obstetrics / Gynecology, found that the effectiveness of adoptive T cell therapy (ACT) in mice with cancer is significantly affected by differences in the natural makeup of gut bacteria and treatment with antibiotics.

This complexity contributes to its aggressive nature and resistance to conventional therapies such as chemotherapy and radiation therapy,» says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at Massey Cancer Center, professor and chair of the Department of Human and Molecular Genetics at the VCU School of Medicine, and director of the VIMM.

In efforts to enhance pre-clinical drug testing, Thomas Gaddy of the University of Southern California, Los Angeles, and colleagues in the research group of Professor Stacey Finley investigated a potential predictive biomarker for a type of cancer drug known as anti-angiogenic therapy.

Lead author Christopher Sweeney, MBBS, associate professor of medicine at Dana Farber Cancer Institute, anticipates these results will be a game changer for therapy guidelines.

«The benefits of early therapy are significant, since it increases the number of healthy life years for patients and decreases their chances of getting serious liver diseases, like liver failure and liver cancer,» said Harinder Chahal, PharmD, MSc, an assistant adjunct professor in the UCSF department of clinical pharmacy.